Design of Digital Image acquisition System Based on FPGA and USB 2.0

随着技术的发展,工业检测技术受到人们的重视,其中图像检测由于其具有直观,方便,信息量较全面而使得它在工业检测方面具有重要的应用。以fPgA作为控制核心,设计了一个小型图像采集系统。通过fPgA实现CMOS图像传感器的初始化、图像数据采集、存储、uSb接口芯片的控制;使用uSb 2.0接口实现图像数据传输;使用VC++编写上位机程序对图像进行实时显示。经过测试,整个系统能够稳定工作,满足设计目标。With the development of technologies,the industrial detection technology has been paid more attention,in which the video detection plays an important roles in the field of industrial detection because of intuitive,convenient and more comprehensive information from it.A small image acquisition system is design by using FPGA as the cotroller.The initialization of CMOS inage sensor,image data acquisition,storage and control of USB interface chip are implemented by using FPGA.The image data is transmitted from FPGA to host via USB 2.0 interface chip,and displayed on the host program.Testing results show that the stability of the whole system meets the design goals

FPGA based image acquisition and processing

在当今信息化时代，智能控制系统得到人们的广泛研究。基于视频信息的智能控制技术是现代智能技术的一个热点领域。视频信息是对周围环境最完备的信息采集方式，但是由于视频信息数据量大、内容复杂，基于传统微控制器的串行计算方法在实时处理和提取视频中关键信息方面一直存在困难，而在移动平台上对视频信息进行实时处理就更加困难。FPGA技术经过多年的发展，从最初的胶合逻辑控制器发展到具有很高性能的复杂逻辑架构，采用FPGA可以构建一个高性能运算平台，从而为视频信息的实时处理提供可能。 本文首先简要介绍了现有图像采集与处理系统的相关技术，同时介绍了FPGA的相关技术理论和基于FPGA系统的开发流程。在此基础上，以...In today's information age,intelligent control systems has attracted more and more attention. Video-based intelligent control technology is a hot field of modern information technology. Video provides the most complete information on the sur-rounding environment. However, due to the large amount of video data and the com-plexity of video information, traditional microprocessor based sequential pro...学位：工学硕士院系专业：物理与机电工程学院物理学系_微电子学与固体电子学学号：1982009115254

The Implementation of Visual Navigation Car Based on FPGA

视觉导航作为新兴起的技术,受众多研究者的青睐.设计了以现场可编程门列阵(fPgA)为控制核心的自主导航小车,采用一种新颖的自适应路径识别算法实现路径的识别与提取,并结合圆弧路线规划和控制策略完成小车的自主导航控制.自适应路径识别算法使导航小车可以适应多种光照和路面条件.测试结果表明,小车能够在不同光照条件下的实验室和露天田径跑道环境中实现较好的导航效果,在田径跑道上的导航测试中,小车的最高运行速度达到3.5M/S.As a new technology,visual navigation has gained a lot of interests.We designed a visual navigation model car with field programmable gate array as central control unit.A novel adaptive track recognition algorithm and a circular arc navigation planning strategy were used in this navigation car.The adaptive track recognition algorithm enabled the model car to navigate visually in multiple lighting and tracking conditions.The ability of our model car to navigate correctly in different indoor and outdoor conditions was demonstrated.During tests on an open track field,the car was to run with a maximum speed of 3.5 m/s while navigating accurately

The Isolation,Identification and Activity Assays of the Myxobacteria

通信作者:[email protected]近年来,粘细菌由于其次级代谢产物结构新颖、生物活性多样而备受关注,成为发展新药的重要来源.利用已灭活酵母菌或大肠杆菌(Escherichia coli)诱导法和滤纸片诱导法等方法进行粘细菌的分离,并采取多种方法对所分离出菌株进行纯化,从95份土样中共分离出118株粘细菌,纯化出54株.根据16SrDNA进行菌株鉴定,主要的粘细菌为粘球菌属(Myxococcus)、珊瑚菌属(Corallococcus)、多囊菌属(Polyangium)和堆囊菌属(Sorangium).对获得纯化的菌株进行了抗菌抗肿瘤活性测定,结果显示有46.3%的菌株具有抗菌作用,有66.7%的菌株具有抗肿瘤作用,表明粘细菌是抗菌抗肿瘤活性物质的重要来源.[英文文摘]Since many different types of 　novel compounds with biological activities are discovered form Myxobacteria,Myxobacteria,become an important resource of medicine.In this experiment,through studying 95 soil and wood samples which were collectd from different regions of China,118Myxobacteria strains were isolated in which 54 isolates were purified.The morphological identification and 16 SrDNA sequencing of 54 Myxobacteria strains showed that they are distributed in 4 genera,and most of them belong to Myxococcus spp.and Sorangium spp ..Antibiotics and anti-tumor activities of the crude extracts of these strains were also tested.科技部国际合作项目(2007DFA30970);中央高校基本业务费(2010121092

Aripiprazole versus other atypical antipsychotics for schizophrenia

BACKGROUND: In most western industrialised countries, second generation (atypical) antipsychotics are recommended as first line drug treatments for people with schizophrenia. In this review we specifically examine how the efficacy and tolerability of one such agent - aripiprazole - differs from that of other comparable second generation antipsychotics. OBJECTIVES: To evaluate the effects of aripiprazole compared with other atypical antipsychotics for people with schizophrenia and schizophrenia-like psychoses. SEARCH METHODS: We searched the Cochrane Schizophrenia Group Trials Register (November 2011), inspected references of all identified studies for further trials, and contacted relevant pharmaceutical companies, drug approval agencies and authors of trials for additional information. SELECTION CRITERIA: We included all randomised clinical trials (RCTs) comparing aripiprazole (oral) with oral and parenteral forms of amisulpride, clozapine, olanzapine, quetiapine, risperidone, sertindole, ziprasidone or zotepine for people with schizophrenia or schizophrenia-like psychoses. DATA COLLECTION AND ANALYSIS: We extracted data independently. For dichotomous data we calculated risk ratios (RR) and their 95% confidence intervals (CI) on an intention-to-treat basis based on a random-effects model. Where possible, we calculated illustrative comparative risks for primary outcomes. For continuous data, we calculated mean differences (MD), again based on a random-effects model. We assessed risk of bias for each included study. MAIN RESULTS: We included 12 trials involving 6389 patients. Aripiprazole was compared to olanzapine, risperidone and ziprasidone. All trials were sponsored by an interested drug manufacturer. The overall number of participants leaving studies early was 30% to 40%, limiting validity (no differences between groups).When compared with olanzapine no differences were apparent for global state (no clinically important change: n = 703, 1 RCT, RR short-term 1.00 95% CI 0.81 to 1.22; n = 317, 1 RCT, RR medium-term 1.08 95% CI 0.95 to 1.22) but mental state tended to favour olanzapine (n = 1360, 3 RCTs, MD total Positive and Negative Syndrome Scale (PANSS) 4.68 95% CI 2.21 to 7.16). There was no significant difference in extrapyramidal symptoms (n = 529, 2 RCTs, RR 0.99 95% CI 0.62 to 1.59) but fewer in the aripiprazole group had increased cholesterol levels (n = 223, 1 RCT, RR 0.32 95% CI 0.19 to 0.54) or weight gain of 7% or more of total body weight (n = 1095, 3 RCTs, RR 0.39 95% CI 0.28 to 0.54).When compared with risperidone, aripiprazole showed no advantage in terms of global state (n = 384, 2 RCTs, RR no important improvement 1.14 95% CI 0.81 to 1.60) or mental state (n = 372, 2 RCTs, MD total PANSS 1.50 95% CI -2.96 to 5.96).One study compared aripiprazole with ziprasidone (n = 247) and both the groups reported similar change in the global state (n = 247, 1 RCT, MD average change in Clinical Global Impression-Severity (CGI-S) score -0.03 95% CI -0.28 to 0.22) and mental state (n = 247, 1 RCT, MD change PANSS -3.00 95% CI -7.29 to 1.29).When compared with any one of several new generation antipsychotic drugs the aripiprazole group showed improvement in global state in energy (n = 523, 1 RCT, RR 0.69 95% CI 0.56 to 0.84), mood (n = 523, 1 RCT, RR 0.77 95% CI 0.65 to 0.92), negative symptoms (n = 523, 1 RCT, RR 0.82 95% CI 0.68 to 0.99), somnolence (n = 523, 1 RCT, RR 0.80 95% CI 0.69 to 0.93) and weight gain (n = 523, 1 RCT, RR 0.84 95% CI 0.76 to 0.94). Significantly more people given aripiprazole reported symptoms of nausea (n = 2881, 3 RCTs, RR 3.13 95% CI 2.12 to 4.61) but weight gain (7% or more of total body weight) was less common in people allocated aripiprazole (n = 330, 1 RCT, RR 0.35 95% CI 0.19 to 0.64). Aripiprazole may have value in aggression but data are limited. This will be the focus of another review. AUTHORS' CONCLUSIONS: Information on all comparisons are of limited quality, are incomplete and problematic to apply clinically. Aripiprazole is an antipsychotic drug with a variant but not absent adverse effect profile. Long-term data are sparse and there is considerable scope for another update of this review as new data emerges from the many Chinese studies as well as from ongoing larger, independent pragmatic trials

JUNO Sensitivity on Proton Decay p→νˉK+p\to \bar\nu K^+ Searches

The Jiangmen Underground Neutrino Observatory (JUNO) is a large liquid scintillator detector designed to explore many topics in fundamental physics. In this paper, the potential on searching for proton decay in $p\to \bar\nu K^+$ mode with JUNO is investigated.The kaon and its decay particles feature a clear three-fold coincidence signature that results in a high efficiency for identification. Moreover, the excellent energy resolution of JUNO permits to suppress the sizable background caused by other delayed signals. Based on these advantages, the detection efficiency for the proton decay via $p\to \bar\nu K^+$ is 36.9% with a background level of 0.2 events after 10 years of data taking. The estimated sensitivity based on 200 kton-years exposure is $9.6 \times 10^{33}$ years, competitive with the current best limits on the proton lifetime in this channel

JUNO sensitivity on proton decay p → ν K + searches*

The Jiangmen Underground Neutrino Observatory (JUNO) is a large liquid scintillator detector designed to explore many topics in fundamental physics. In this study, the potential of searching for proton decay in the $p\to \bar{\nu} K^+$ mode with JUNO is investigated. The kaon and its decay particles feature a clear three-fold coincidence signature that results in a high efficiency for identification. Moreover, the excellent energy resolution of JUNO permits suppression of the sizable background caused by other delayed signals. Based on these advantages, the detection efficiency for the proton decay via $p\to \bar{\nu} K^+$ is 36.9% ± 4.9% with a background level of $0.2\pm 0.05({\rm syst})\pm$$0.2({\rm stat})$ events after 10 years of data collection. The estimated sensitivity based on 200 kton-years of exposure is $9.6 \times 10^{33}$ years, which is competitive with the current best limits on the proton lifetime in this channel and complements the use of different detection technologies